Most Read Articles
21 Aug 2019
Daily use of the selective oral Bruton’s tyrosine kinase inhibitor evobrutinib in the treatment of patients with relapsing multiple sclerosis helps reduce the number of gadolinium-enhancing lesions, according to the results of a phase II trial.
20 Aug 2019
The combination of pravastatin and sorafenib does not appear to improve survival in patients with hepatocellular carcinoma (HCC), a recent study has shown.
03 Apr 2019
Long-term treatment with glucocorticoids (GC) is necessary in polymyalgia rheumatica (PMR), but preliminary data of a study suggests that use of amino bisphosphonates (N-BP) correlates with GC discontinuation in the management of PMR.
Roshini Claire Anthony, 20 Aug 2019

The combination of emtricitabine and dolutegravir with either a tenofovir alafenamide fumarate (TAF) or tenofovir disoproxil fumarate (TDF)-based regimen fared similarly to a TDF-emtricitabine-efavirenz regimen in reducing HIV-1 RNA levels, according to results of the phase III ADVANCE* study presented at IAS 2019.

Intrauterine exposure to oral contraceptives marginally affects pubertal timing

08 Sep 2019

Children exposed to oral contraceptives (OCs) early in pregnancy tend to start puberty and achieve some pubertal milestones at an earlier age, although the magnitude of effect is small and imprecise, a study has found.

The analysis included 15,800 children born during 2000–2003 into the Danish National Birth Cohort, grouped according to maternal use of combined OC pills or progestin-only pills reported around gestational week 17: no exposure (reference; n=11,828), exposure 4 months before conception (n=3,518) and exposure in early pregnancy (n=454). Children self-assessed pubertal status by completing web-based questionnaires from 11 years and biannually throughout puberty.

Intrauterine exposure to OCs showed a tendency toward slightly earlier mean age of achieving some individual pubertal milestones and overall pubertal timing. Specific milestones included voice break (months, −3.8; 95 percent CI, −6.5 to −1.0) and first ejaculation (months, −2.9, −5.9 to 0.1) in boys, and menarche (months, −1.9, −4.0 to 0.3) and Tanner breast stages in girls. The mean age difference for overall pubertal timing was −1.4 months (−3.3 to 0.4) in boys and −0.9 months (−2.7 to 1.0) in girls.

OC exposure prior to conception was not associated with pubertal timing. Furthermore, prepubertal body mass index did not exhibit a mediating effect.

Additional studies are needed, particularly those that that can distinguish between formulations of OCs and timing of exposure in foetal life, owing to the study limitations and rarity of the exposure, researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
21 Aug 2019
Daily use of the selective oral Bruton’s tyrosine kinase inhibitor evobrutinib in the treatment of patients with relapsing multiple sclerosis helps reduce the number of gadolinium-enhancing lesions, according to the results of a phase II trial.
20 Aug 2019
The combination of pravastatin and sorafenib does not appear to improve survival in patients with hepatocellular carcinoma (HCC), a recent study has shown.
03 Apr 2019
Long-term treatment with glucocorticoids (GC) is necessary in polymyalgia rheumatica (PMR), but preliminary data of a study suggests that use of amino bisphosphonates (N-BP) correlates with GC discontinuation in the management of PMR.
Roshini Claire Anthony, 20 Aug 2019

The combination of emtricitabine and dolutegravir with either a tenofovir alafenamide fumarate (TAF) or tenofovir disoproxil fumarate (TDF)-based regimen fared similarly to a TDF-emtricitabine-efavirenz regimen in reducing HIV-1 RNA levels, according to results of the phase III ADVANCE* study presented at IAS 2019.